Abstract
Modulation of inflammasomes has tremendous therapeutic potential and is hotly pursued by industry and academia alike. Indeed a growing number of patents are emerging to protect the intellectual property in valuable compound classes. This chapter focusses specifically on the suite of small-molecule NLRP3 inflammasome inhibitors published, as specific modulation of other inflammasomes is not yet well established. Synthetic molecules, known drugs and natural product NLRP3 modulators will be detailed. Some of the molecular classes discussed have been extensively characterised through cell-based screening, pharmacokinetic profiling and therapeutic proof of concept animal models. However, many inhibitors lack rigorous studies and/or have multiple activities of which NLRP3 modulation is only one. While this is not intended as an exhaustive list, it should give an impression of the range of structures and strategies that are being used, alongside challenges encountered, in an effort to exploit the significant therapeutic benefits of targeting inflammasomes.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abderrazak A, Couchie D, Mahmood DF, Elhage R, Vindis C, Laffargue M, Mateo V, Buchele B, Ayala MR, El Gaafary M, Syrovets T, Slimane MN, Friguet B, Fulop T, Simmet T, El Hadri K, Rouis M (2015) Anti-inflammatory and antiatherogenic effects of the NLRP3 inflammasome inhibitor arglabin in ApoE2.Ki mice fed a high-fat diet. Circulation 131(12):1061–1070. https://doi.org/10.1161/CIRCULATIONAHA.114.013730
Abderrazak A, El Hadri K, Bosc E, Blondeau B, Slimane MN, Buchele B, Simmet T, Couchie D, Rouis M (2016) Inhibition of the inflammasome NLRP3 by arglabin attenuates inflammation, protects pancreatic beta-Cells from apoptosis, and prevents type 2 diabetes mellitus development in ApoE2Ki mice on a chronic high-fat diet. J Pharmacol Exp Ther 357(3):487–494. https://doi.org/10.1124/jpet.116.232934
Ackermann TF, Boini KM, Beier N, Scholz W, Fuchss T, Lang F (2011) EMD638683, a novel SGK inhibitor with antihypertensive potency. Cell Physiol Biochem 28(1):137–146. https://doi.org/10.1159/000331722
Administration USFaD (2017a) Drugs@FDA: FDA approved drug products. New drug application 209176. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209176. Accessed 15 Nov 2017
Administration USFaD (2017b) FDA approves drug to treat ALS. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm557102.htm. Accessed 15 Nov 2017
Ahmad I, Muneer K, Tamimi I, Chang M, Ata M, Yusuf N (2013) Thymoquinone suppresses metastasis of melanoma cells by inhibition of NLRP3 inflammasome. Toxicol Appl Pharmacol 270:70–76. https://doi.org/10.1016/j.taap.2013.03.027
Ahn H, Lee G-S (2017) Isorhamnetin and hyperoside derived from water dropwort inhibits inflammasome activation. Phytomedicine 24:77–86. https://doi.org/10.1016/j.phymed.2016.11.019
Alcocer-Gomez E, Casas-Barquero N, Williams MR, Romero-Guillena SL, Canadas-Lozano D, Bullon P, Sanchez-Alcazar JA, Navarro-Pando JM, Cordero MD (2017) Antidepressants induce autophagy dependent-NLRP3-inflammasome inhibition in major depressive disorder. Pharmacol Res 121:114–121. https://doi.org/10.1016/j.phrs.2017.04.028
Aldieri E, Atragene D, Bergandi L, Riganti C, Costamagna C, Bosia A, Ghigo D (2003) Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-kB activation. FEBS Lett 552(2–3):141–144. https://doi.org/10.1016/S0014-5793(03)00905-0
Aruna R, Geetha A, Suguna P (2014) Rutin modulates ASC expression in NLRP3 inflammasome: a study in alcohol and cerulein-induced rat model of pancreatitis. Mol Cell Biochem 396:269–280. https://doi.org/10.1007/s11010-014-2162-8
Ashcroft FM (2005) ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest 115(8):2047–2058. https://doi.org/10.1172/JCI25495
Baldwin AG, Rivers-Auty J, Daniels MJD, White CS, Schwalbe CH, Schilling T, Hammadi H, Jaiyong P, Spencer NG, England H, Luheshi NM, Kadirvel M, Lawrence CB, Rothwell NJ, Harte MK, Bryce RA, Allan SM, Eder C, Freeman S, Brough D (2017) Boron-based inhibitors of the NLRP3 inflammasome. Cell Chem Biol 24(11):1321–1335. https://doi.org/10.1016/j.chembiol.2017.08.011
Barbaro NR, Fontana V, Modolo R, De Faria AP, Sabbatini AR, Fonseca FH, Anhe GF, Moreno H (2015) Increased arterial stiffness in resistant hypertension is associated with inflammatory biomarkers. Blood Press 24(1):7–13. https://doi.org/10.3109/08037051.2014.940710
Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, Cooper MA, Cleveland JL, O’Neill LA, Wei S, List AF (2016) The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood 128(25):2960–2975. https://doi.org/10.1182/blood-2016-07-730556
Boriushkin E, Wang JJ, Li J, Bhatta M, Zhang SX (2016) p58(IPK) suppresses NLRP3 inflammasome activation and IL-1beta production via inhibition of PKR in macrophages. Sci Rep 6:25013. https://doi.org/10.1038/srep25013
Brough D, Allan SM, Freeman S, Baldwin AG (2017) Cyclic diarylboron derivatives as NLRP3 inflammasome inhibitors. University of Manchester. WO/2017/017469
Brydges SD, Mueller JL, McGeough MD, Pena CA, Misaghi A, Gandhi C, Putnam CD, Boyle DL, Firestein GS, Horner AA, Soroosh P, Watford WT, O’Shea JJ, Kastner DL, Hoffman HM (2009) Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity 30(6):875–887. https://doi.org/10.1016/j.immuni.2009.05.005
Bugyei-Twum A, Abadeh A, Thai K, Zhang Y, Mitchell M, Kabir G, Connelly KA (2016) Suppression of NLRP3 inflammasome activation ameliorates chronic kidney disease-induced cardiac fibrosis and diastolic dysfunction. Sci Rep 6:39551. https://doi.org/10.1038/srep39551
Cassidy A, Minihane AM (2017) The role of metabolism (and the microbiome) in defining the clinical efficacy of dietary flavonoids. Am J Clin Nutr 105(1):10–22. https://doi.org/10.3945/ajcn.116.136051
Chang YP, Ka SM, Hsu WH, Chen A, Chao LK, Lin CC, Hsieh CC, Chen MC, Chiu HW, Ho CL, Chiu YC, Liu ML, Hua KF (2015) Resveratrol inhibits NLRP3 inflammasome activation by preserving mitochondrial integrity and augmenting autophagy. J Cell Physiol 230(7):1567–1579. https://doi.org/10.1002/jcp.24903
Chavarria-Smith J, Vance RE (2015) The NLRP1 inflammasomes. Immunol Rev 265(1):22–34. https://doi.org/10.1111/imr.12283
Chung IC, OuYang CN, Yuan SN, Li HP, Chen JT, Shieh HR, Chen YJ, Ojcius DM, Chu CL, Yu JS, Chang YS, Chen LC (2016) Pyk2 activates the NLRP3 inflammasome by directly phosphorylating ASC and contributes to inflammasome-dependent peritonitis. Sci Rep 6:36214. https://doi.org/10.1038/srep36214
Co Ha (19 Nov 2016) Harnessing the clinical potential of sulforaphane. http://www.directorstalkinterviews.com/evgen-pharma-plc-harnessing-clinical-potential-sulforaphane/412717321. Accessed 09 Nov 2017
Cocco M, Garella D, Di Stilo A, Borretto E, Stevanato L, Giorgis M, Marini E, Fantozzi R, Miglio G, Bertinaria M (2014) Electrophilic warhead-based design of compounds preventing NLRP3 inflammasome-dependent pyroptosis. J Med Chem 57(24):10366–10382. https://doi.org/10.1021/jm501072b
Cocco M, Miglio G, Giorgis M, Garella D, Marini E, Costale A, Regazzoni L, Vistoli G, Orioli M, Massulaha-Ahmed R, Detraz-Durieux I, Groslambert M, Py BF, Bertinaria M (2016) Design, synthesis, and evaluation of acrylamide derivatives as direct NLRP3 inflammasome inhibitors. ChemMedChem 11(16):1790–1803. https://doi.org/10.1002/cmdc.201600055
Cocco M, Pellegrini C, Martinez-Banadocha H, Giorgis M, Marini E, Costale A, Miglio G, Fomai M, Antonioli L, Lopez-Castejon G, Tapia-Abellan A, Angosto D, Hafner-Bratkovic I, Regazzoni L, Blandizzi C, Pelegrin P, Bertinaria M (2017) Development of an acrylate derivative targeting the NLRP3 inflammasome for the treatment of inflammatory bowel disease. J Med Chem 60(9):3656–3671. https://doi.org/10.1021/acs.jmedchem.6b01624
Coll RC, Robertson A, Butler M, Cooper M, O’Neill LA (2011) The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes. PLoS One 6(12):e29539. https://doi.org/10.1371/journal.pone.0029539
Coll RC, Robertson AA, Chae JJ, Higgins SC, Munoz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG, Stutz A, Croker DE, Butler MS, Haneklaus M, Sutton CE, Nunez G, Latz E, Kastner DL, Mills KH, Masters SL, Schroder K, Cooper MA, O’Neill LA (2015) A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 21(3):248–255. https://doi.org/10.1038/nm.3806
Corporation NP (2011) Highlights of prescribing information: Ilaris (canakinumab). https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125319s047lbl.pdf. Accessed 15 Nov 2017
D’Anneo A, Carlisi D, Lauricella M, Puleio R, Martinez R, Di Bella S, Di Marco P, Emanuele S, Di Fiore R, Guercio A, Vento R, Tesoriere G (2013) Parthenolide generates reactive oxygen species and autophagy in MDA-MB231 cells. A soluble parthenolide analogue inhibits tumour growth and metastasis in a xenograft model of breast cancer. Cell Death Dis 4:e891. https://doi.org/10.1038/cddis.2013.415
Dai YF, Zhou WW, Meng J, Du XL, Sui YP, Dai L, Wang PQ, Huo HR, Sui F (2017) The pharmacological activities and mechanisms of artemisinin and its derivatives: a systematic review. Med Chem Res 26(5):867–880. https://doi.org/10.1007/s00044-016-1778-5
Dalekos GN, Elisaf M, Bairaktari E, Tsolas O, Siamopoulos KC (1997) Increased serum levels of interleukin-1beta in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients? J Lab Clin Med 129(3):300–308. https://doi.org/10.1016/S0022-2143(97)90178-5
Daniels MJ, Rivers-Auty J, Schilling T, Spencer NG, Watremez W, Fasolino V, Booth SJ, White CS, Baldwin AG, Freeman S, Wong R, Latta C, Yu S, Jackson J, Fischer N, Koziel V, Pillot T, Bagnall J, Allan SM, Paszek P, Galea J, Harte MK, Eder C, Lawrence CB, Brough D (2016) Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models. Nat Commun 7:12504. https://doi.org/10.1038/ncomms12504
Dempsey C, Rubio Araiz A, Bryson KJ, Finucane O, Larkin C, Mills EL, Robertson AAB, Cooper MA, O’Neill LAJ, Lynch MA (2017) Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-beta and cognitive function in APP/PS1 mice. Brain Behav Immun 61:306–316. https://doi.org/10.1016/j.bbi.2016.12.014
Dey S, Sarkar M, Giri B (2016) Anti-inflammatory and anti-tumor activities of parthenolide: an update. J Chem Biol Therp 1(2):107. https://doi.org/10.4172/2572-0406.1000107
Dinarello CA (2010) Anti-inflammatory agents: present and future. Cell 140(6):935–950. https://doi.org/10.1016/j.cell.2010.02.043
Dinh QN, Drummond GR, Kemp-Harper BK, Diep H, De Silva TM, Kim HA, Vinh A, Robertson AAB, Cooper MA, Mansell A, Chrissobolis S, Sobey CG (2017) Pressor response to angiotensin II is enhanced in aged mice and associated with inflammation, vasoconstriction and oxidative stress. Aging (Albany NY) 9(6):1595–1606. https://doi.org/10.18632/aging.101255
Dombroski MA, Eggler JF (1998) Sulfonyl urea derivatives and their use in the control of interleukin-1 activity. Pfizer Inc. WO1998032733
Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, Hultcrantz R (2015) Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61(5):1547–1554. https://doi.org/10.1002/hep.27368
Ellis LZ, Liu W, Luo Y, Okamoto M, Qu D, Dunn JH, Fujita M (2011) Green tea polyphenol epigallocatechin-3-gallate suppresses melanoma growth by inhibiting inflammasome and IL-1beta secretion. Biochem Biophys Res Commun 414(3):551–556. https://doi.org/10.1016/j.bbrc.2011.09.115
Fernandes-Alnemri T, Kang S, Anderson C, Sagara J, Fitzgerald KA, Alnemri ES (2013) Cutting edge: TLR signaling licenses IRAK1 for rapid activation of the NLRP3 inflammasome. J Immunol 191(8):3995–3999. https://doi.org/10.4049/jimmunol.1301681
Fu Y, Wang Y, Du L, Xu C, Cao J, Fan T, Liu J, Su X, Fan S, Liu Q, Fan F (2013) Resveratrol inhibits ionising irradiation-induced inflammation in MSCs by activating SIRT1 and limiting NLRP-3 inflammasome activation. Int J Mol Sci 14(7):14105–14118. https://doi.org/10.3390/ijms140714105
Fu SP, Wang JF, Xue WJ, Liu HM, Liu BR, Zeng YL, Li SN, Huang BX, Lv QK, Wang W, Liu JX (2015) Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson’s disease models are mediated by GPR109A-dependent mechanisms. J Neuroinflammation 12:9. https://doi.org/10.1186/s12974-014-0230-3
Fu J, Sun H, Zhang Y, Xu W, Wang C, Fang Y, Zhao J (2017) Neuroprotective effects of luteolin against spinal cord ischemia-reperfusion injury by attenuation of oxidative stress, inflammation, and apoptosis. J Med Food 21(1):13–20. https://doi.org/10.1089/jmf.2017.4021
Gan W, Ren J, Li T, Lv S, Li C, Liu Z, Yang M (2017) The SGK1 inhibitor EMD638683, prevents Angiotensin II-induced cardiac inflammation and fibrosis by blocking NLRP3 inflammasome activation. Biochim Biophys Acta 1864(1):1–10. https://doi.org/10.1016/j.bbadis.2017.10.001
Gao Y-Z, Zhao L-F, Ma J, Xue W-H, Zhao H (2016) Protective mechanisms of wogonoside against Lipopolysaccharide/D-galactosamine-induced acute liver injury in mice. Eur J Pharmacol 780:8–15. https://doi.org/10.1016/j.ejphar.2016.02.040
Gehringer M, Muth F, Koch P, Laufer SA (2015) c-Jun N-terminal kinase inhibitors: a patent review (2010-2014). Expert Opin Ther Pat 25(8):849–872. https://doi.org/10.1517/13543776.2015.1039984
Goldbach-Mansky R, Wilson M, Fleischmann R, Olsen N, Silverfield J, Kempf P, Kivitz A, Sherrer Y, Pucino F, Csako G, Costello R, Pham TH, Snyder C, van der Heijde D, Tao X, Wesley R, Lipsky PE (2009) Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Ann Intern Med 151(4):229–240 W249-251
Gong Z, Zhou J, Li H, Gao Y, Xu C, Zhao S, Chen Y, Cai W, Wu J (2015) Curcumin suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock. Mol Nutr Food Res 59(11):2132–2142. https://doi.org/10.1002/mnfr.201500316
Greaney AJ, Maier NK, Leppla SH, Moayeri M (2016) Sulforaphane inhibits multiple inflammasomes through an Nrf2-independent mechanism. J Leukoc Biol 99(1):189–199. https://doi.org/10.1189/jlb.3A0415-155RR
Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID (2002) Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 57(10):875–879
Gris D, Ye Z, Iocca HA, Wen H, Craven RR, Gris P, Huang M, Schneider M, Miller SD, Ting JP (2010) NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J Immunol 185(2):974–981. https://doi.org/10.4049/jimmunol.0904145
Gross CJ, Mishra R, Schneider KS, Medard G, Wettmarshausen J, Dittlein DC, Shi H, Gorka O, Koenig PA, Fromm S, Magnani G, Cikovic T, Hartjes L, Smollich J, Robertson AA, Cooper MA, Schmidt-Supprian M, Schuster M, Schroder K, Broz P, Traidl-Hoffmann C, Beutler B, Kuster B, Ruland J, Schneider S, Perocchi F, Gross O (2016) K+ Efflux-Independent NLRP3 Inflammasome Activation by Small Molecules Targeting Mitochondria. Immunity 45(4):761–773. https://doi.org/10.1016/j.immuni.2016.08.010
Grundmann S, Bode C, Moser M (2011) Inflammasome activation in reperfusion injury: friendly fire on myocardial infarction? Circulation 123(6):574–576. https://doi.org/10.1161/CIRCULATIONAHA.111.018176
Guo A, He D, Xu HB, Geng CA, Zhao J (2015) Promotion of regulatory T cell induction by immunomodulatory herbal medicine licorice and its two constituents. Sci Rep 5:14046. https://doi.org/10.1038/srep14046
Guo C, Fulp JW, Jiang Y, Li X, Chojnacki JE, Wu J, Wang XY, Zhang S (2017) Development and characterization of a hydroxyl-sulfonamide analogue, 5-chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a novel NLRP3 inflammasome inhibitor for potential treatment of Multiple Sclerosis. ACS Chem Neurosci 8(10):2194–2201. https://doi.org/10.1021/acschemneuro.7b00124
Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennett JM, Sullivan E, Lachowicz JL, Vaughan A, Sweeney CJ, Matthews W, Carroll M, Liesveld JL, Crooks PA, Jordan CT (2007) An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 110(13):4427–4435. https://doi.org/10.1182/blood-2007-05-090621
Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ, Golenbock DT (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9(8):857–865. https://doi.org/10.1038/ni.1636
Hamon Y, Luciani MF, Becq F, Verrier B, Rubartelli A, Chimini G (1997) Interleukin-1beta secretion is impaired by inhibitors of the Atp binding cassette transporter, ABC1. Blood 90(8):2911–2915
Han SC, Cai WX, Yang XK, Jia YH, Zheng Z, Wang HT, Li J, Li Y, Gao JX, Fan L, Hu DH (2015) ROS-,ediated NLRP3 inflammasome activity is essential for burn-induced acute lung injury. Mediat Inflamm. Artn 720457. https://doi.org/10.1155/2015/720457
Hara H, Tsuchiya K, Kawamura I, Fang R, Hernandez-Cuellar E, Shen Y, Mizuguchi J, Schweighoffer E, Tybulewicz V, Mitsuyama M (2013) Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity. Nat Immunol 14(12):1247–1257. https://doi.org/10.1038/ni.2749
Hastie AT, Moore WC, Meyers DA, Vestal PL, Li H, Peters SP, Bleecker ER (2010) Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol 125(5):1028–1036 e1013. https://doi.org/10.1016/j.jaci.2010.02.008
He Y, Varadarajan S, Munoz-Planillo R, Burberry A, Nakamura Y, Nunez G (2014) 3,4-methylenedioxy-beta-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J Biol Chem 289(2):1142–1150. https://doi.org/10.1074/jbc.M113.515080
He Y, Hara H, Nunez G (2016a) Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci 41(12):1012–1021. https://doi.org/10.1016/j.tibs.2016.09.002
He Y, Zeng MY, Yang D, Motro B, Nunez G (2016b) NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature 530(7590):354–357. https://doi.org/10.1038/nature16959
Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA (2012) Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482(7384):179–185. https://doi.org/10.1038/nature10809
Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, Gelpi E, Halle A, Korte M, Latz E, Golenbock DT (2013) NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature 493(7434):674. https://doi.org/10.1038/nature11729
Higdon J, Drake V, Delage B, Crozier A (2005) Flavonoids. Linus Pauling Institute, Oregon State University. http://lpi.oregonstate.edu/mic/dietary-factors/phytochemicals/flavonoids. Accessed 12 Nov 2017
Hill JR, Coll RC, Sue N, Reid JC, Dou J, Holley CL, Pelingon R, Dickinson JB, Biden TJ, Schroder K, Cooper MA, Robertson AAB (2017) Sulfonylureas as concomitant insulin secretagogues and NLRP3 inflammasome inhibitors. ChemMedChem 12(17):1449–1457. https://doi.org/10.1002/cmdc.201700270
Honda H, Nagai Y, Matsunaga T, Okamoto N, Watanabe Y, Tsuneyama K, Hayashi H, Fujii I, Ikutani M, Hirai Y, Muraguchi A, Takatsu K (2014) Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation. J Leukoc Biol 96(6):1087–1100. https://doi.org/10.1189/jlb.3A0114-005RR
Hostetler G, Riedl K, Cardenas H, Diosa-Toro M, Arango D, Schwartz S, Doseff AI (2012) Flavone deglycosylation increases their anti-inflammatory activity and absorption. Mol Nutr Food Res 56(4):558–569. https://doi.org/10.1002/mnfr.201100596
Ito K, Chung KF, Adcock IM (2006) Update on glucocorticoid action and resistance. J Allergy Clin Immunol 117(3):522–543. https://doi.org/10.1016/j.jaci.2006.01.032
Ito M, Shichita T, Okada M, Komine R, Noguchi Y, Yoshimura A, Morita R (2015) Bruton’s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury. Nat Commun 6:7360. https://doi.org/10.1038/ncomms8360
Ives A, Nomura J, Martinon F, Roger T, LeRoy D, Miner JN, Simon G, Busso N, So A (2015) Xanthine oxidoreductase regulates macrophage IL1beta secretion upon NLRP3 inflammasome activation. Nat Commun 6:6555. https://doi.org/10.1038/ncomms7555
Jiang L, Zhang L, Kang K, Fei DS, Gong R, Cao YH, Pan SH, Zhao MR, Zhao MY (2016a) Resveratrol ameliorates LPS-induced acute lung injury via NLRP3 inflammasome modulation. Biomed Pharmacother 84:130–138. https://doi.org/10.1016/j.biopha.2016.09.020
Jiang W, He F, Li M, Bian Z, Zhu L, Huang Y, Han N, Liu J, Sun T (2016b) Quercetin suppresses NLRP3 inflammasome activation and attenuates histopathology in a rat model of spinal cord injury. Spinal Cord 54(6):592–596. https://doi.org/10.1038/sc.2015.227
Jiang H, He H, Chen Y, Huang W, Cheng J, Ye J, Wang A, Tao J, Wang C, Liu Q, Jin T, Jiang W, Deng X, Zhou R (2017) Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med 214(11):3219–3238. https://doi.org/10.1084/jem.20171419
Juliana C, Fernandes-Alnemri T, Wu J, Datta P, Solorzano L, Yu JW, Meng R, Quong AA, Latz E, Scott CP, Alnemri ES (2010) Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J Biol Chem 285(13):9792–9802. https://doi.org/10.1074/jbc.M109.082305
Katsnelson MA, Rucker LG, Russo HM, Dubyak GR (2015) K+ Efflux agonists induce NLRP3 inflammasome activation independently of Ca2+ signaling. J Immunol 194(8):3937. https://doi.org/10.4049/jimmunol.1402658
Kaufmann FN, Costa AP, Ghisleni G, Diaz AP, Rodrigues ALS, Peluffo H, Kaster MP (2017) NLRP3 inflammasome-driven pathways in depression: clinical and preclinical findings. Brain Behav Immun 64:367–383. https://doi.org/10.1016/j.bbi.2017.03.002
Khan MA, Tania M, Fu SY, Fu JJ (2017) Thymoquinone, as an anticancer molecule: from basic research to clinical investigation. Oncotarget 8(31):51907–51919. https://doi.org/10.18632/oncotarget.17206
Kim RY, Pinkerton JW, Essilfie AT, Robertson AA, Baines KJ, Brown AC, Mayall JR, Ali MK, Starkey MR, Hansbro NG, Hirota JA, Wood LG, Simpson JL, Knight DA, Wark PA, Gibson PG, O’Neill LA, Cooper MA, Horvat JC, Hansbro PM (2017) Role for NLRP3 inflammasome-mediated, IL-1beta-dependent responses in severe, steroid-resistant asthma. Am J Respir Crit Care Med. https://doi.org/10.1164/rccm.201609-1830OC
Koh GC, Maude RR, Schreiber MF, Limmathurotsakul D, Wiersinga WJ, Wuthiekanun V, Lee SJ, Mahavanakul W, Chaowagul W, Chierakul W, White NJ, van der Poll T, Day NP, Dougan G, Peacock SJ (2011) Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis. Clin Infect Dis 52(6):717–725. https://doi.org/10.1093/cid/ciq192
Kong F, Ye B, Cao J, Cai X, Lin L, Huang S, Huang W, Huang Z (2016) Curcumin represses NLRP3 inflammasome activation via TLR4/MyD88/NF-kappaB and P2X7R signaling in PMA-induced macrophages. Front Pharmacol 7:369. https://doi.org/10.3389/fphar.2016.00369
Koo JW, Duman RS (2008) IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci U S A 105(2):751–756. https://doi.org/10.1073/pnas.0708092105
Krishnan SM, Dowling JK, Ling YH, Diep H, Chan CT, Ferens D, Kett MM, Pinar A, Samuel CS, Vinh A, Arumugam TV, Hewitson TD, Kemp-Harper BK, Robertson AA, Cooper MA, Latz E, Mansell A, Sobey CG, Drummond GR (2016) Inflammasome activity is essential for one kidney/deoxycorticosterone acetate/salt-induced hypertension in mice. Br J Pharmacol 173(4):752–765. https://doi.org/10.1111/bph.13230
Lai MZ, Chen RH (2014) Regulation of inflammation by DAPK. Apoptosis 19(2):357–363. https://doi.org/10.1007/s10495-013-0933-4
Laliberte RE, Eggler J, Gabel CA (1999) ATP treatment of human monocytes promotes caspase-1 maturation and externalization. J Biol Chem 274(52):36944–36951
Laliberte RE, Perregaux DG, Hoth LR, Rosner PJ, Jordan CK, Peese KM, Eggler JF, Dombroski MA, Geoghegan KF, Gabel CA (2003) Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing. J Biol Chem 278(19):16567–16578. https://doi.org/10.1074/jbc.M211596200
Lalor SJ, Dungan LS, Sutton CE, Basdeo SA, Fletcher JM, Mills KH (2011) Caspase-1-processed cytokines IL-1beta and IL-18 promote IL-17 production by gammadelta and CD4 T cells that mediate autoimmunity. J Immunol 186(10):5738–5748. https://doi.org/10.4049/jimmunol.1003597
Lamkanfi M, Mueller JL, Vitari AC, Misaghi S, Fedorova A, Deshayes K, Lee WP, Hoffman HM, Dixit VM (2009) Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol 187(1):61–70. https://doi.org/10.1083/jcb.200903124
LaRock CN, Todd J, LaRock DL, Olson J, O’Donoghue AJ, Robertson AAB, Cooper MA, Hoffman HM, Nizet V (2016) IL-1beta is an innate immune sensor of microbial proteolysis. Sci Immunol 1(2):eaah3539. https://doi.org/10.1126/sciimmunol.aah3539
Latz E, Xiao TS, Stutz A (2013) Activation and regulation of the inflammasomes. Nat Rev Immunol 13(6):397–411. https://doi.org/10.1038/nri3452
Lee H, Shin EA, Lee JH, Ahn D, Kim CG, Kim JH, Kim SH (2017) Caspase inhibitors: a review of recently patented compounds (2013-2015). Expert Opin Ther Pat:1–13. https://doi.org/10.1080/13543776.2017.1378426
Li S, Gao X, Wu X, Wu Z, Cheng L, Zhu L, Shen D, Tong X (2015) Parthenolide inhibits LPS-induced inflammatory cytokines through the toll-like receptor 4 signal pathway in THP-1 cells. Acta Biochim Biophys Sin Shanghai 47(5):368–375. https://doi.org/10.1093/abbs/gmv019
Li A, Zhang S, Li J, Liu K, Huang F, Liu B (2016a) Metformin and resveratrol inhibit Drp1-mediated mitochondrial fission and prevent ER stress-associated NLRP3 inflammasome activation in the adipose tissue of diabetic mice. Mol Cell Endocrinol 434:36–47. https://doi.org/10.1016/j.mce.2016.06.008
Li R, Wang X, Qin T, Qu R, Ma S (2016b) Apigenin ameliorates chronic mild stress-induced depressive behavior by inhibiting interleukin-1beta production and NLRP3 inflammasome activation in the rat brain. Behav Brain Res 296:318–325. https://doi.org/10.1016/j.bbr.2015.09.031
Li H, Lin S, Qin T, Li H, Ma Z, Ma S (2017) Senegenin exerts anti-depression effect in mice induced by chronic un-predictable mild stress via inhibition of NF-kappaB regulating NLRP3 signal pathway. Int Immunopharmacol 53:24–32. https://doi.org/10.1016/j.intimp.2017.10.001
Lin KM, Hu W, Troutman TD, Jennings M, Brewer T, Li XX, Nanda S, Cohen P, Thomas JA, Pasare C (2014) IRAK-1 bypasses priming and directly links TLRs to rapid NLRP3 inflammasome activation. Proc Natl Acad Sci U S A 111(2):775–780. https://doi.org/10.1073/pnas.1320294111
Lin YC, Huang DY, Wang JS, Lin YL, Hsieh SL, Huang KC, Lin WW (2015) Syk is involved in NLRP3 inflammasome-mediated caspase-1 activation through adaptor ASC phosphorylation and enhanced oligomerization. J Leukoc Biol 97(5):825–835. https://doi.org/10.1189/jlb.3HI0814-371RR
Liu D, Mamorska-Dyga A (2017) Syk inhibitors in clinical development for hematological malignancies. J Hematol Oncol 10(1):145. https://doi.org/10.1186/s13045-017-0512-1
Liu W, Guo W, Wu J, Luo Q, Tao F, Gu Y, Shen Y, Li J, Tan R, Xu Q, Sun Y (2013) A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome. Biochem Pharmacol 85(10):1504–1512. https://doi.org/10.1016/j.bcp.2013.03.008
Long HB, Xu BC, Luo YL, Luo KQ (2016) Artemisinin protects mice against burn sepsis through inhibiting NLRP3 inflammasome activation. Am J Emerg Med 34(5):772–777. https://doi.org/10.1016/j.ajem.2015.12.075
Lu M, Yin N, Liu W, Cui X, Chen S, Wang E (2017) Curcumin ameliorates diabetic nephropathy by suppressing NLRP3 inflammasome signaling. Biomed Res Int 2017:1516985. https://doi.org/10.1155/2017/1516985
Ludwig-Portugall I, Bartok E, Dhana E, Evers BD, Primiano MJ, Hall JP, Franklin BS, Knolle PA, Hornung V, Hartmann G, Boor P, Latz E, Kurts C (2016) An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice. Kidney Int 90(3):525–539. https://doi.org/10.1016/j.kint.2016.03.035
MacKenzie SH, Schipper JL, Clark AC (2010) The potential for caspases in drug discovery. Curr Opin Drug Discov Devel 13(5):568–576
Marble A (1971) Glibenclamide, a new sulphonylurea: whither oral hypoglycaemic agents? Drugs 1(2):109–115
Marchetti C, Chojnacki J, Toldo S, Mezzaroma E, Tranchida N, Rose SW, Federici M, Van Tassell BW, Zhang S, Abbate A (2014) A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse. J Cardiovasc Pharmacol 63(4):316–322. https://doi.org/10.1097/FJC.0000000000000053
Marchetti C, Toldo S, Chojnacki J, Mezzaroma E, Liu K, Salloum FN, Nordio A, Carbone S, Mauro AG, Das A, Zalavadia AA, Halquist MS, Federici M, Van Tassell BW, Zhang S, Abbate A (2015) Pharmacologic inhibition of the NLRP3 inflammasome preserves cardiac function after ischemic and nonischemic injury in the mouse. J Cardiovasc Pharmacol 66(1):1–8. https://doi.org/10.1097/FJC.0000000000000247
Marty V, Medina C, Combe C, Parnet P, Amedee T (2005) ATP binding cassette transporter ABC1 is required for the release of interleukin-1beta by P2X7-stimulated and lipopolysaccharide-primed mouse Schwann cells. Glia 49(4):511–519. https://doi.org/10.1002/glia.20138
Miyaji Y, Yoshimura S, Sakai N, Yamagami H, Egashira Y, Shirakawa M, Uchida K, Kageyama H, Tomogane Y (2015) Effect of edaravone on favorable outcome in patients with acute cerebral large vessel occlusion: subanalysis of RESCUE-Japan Registry. Neurol Med Chir (Tokyo) 55(3):241–247. https://doi.org/10.2176/nmc.ra.2014-0219
Mridha AR, Wree A, Robertson AA, Yeh MM, Johnson CD, Van Rooyen DM, Haczeyni F, Teoh NC, Savard C, Ioannou GN, Masters SL, Schroder K, Cooper MA, Feldstein AE, Farrell GC (2017) NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol 66(5):1037–1046. https://doi.org/10.1016/j.jhep.2017.01.022
Mulay SR, Evan A, Anders HJ (2014) Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease. Nephrol Dial Transplant 29(3):507–514. https://doi.org/10.1093/ndt/gft248
Murphy JJ, Heptinstall S, Mitchell JR (1988) Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 2(8604):189–192. https://doi.org/10.1016/S0140-6736(88)92289-1
Neumann K, Ruland J (2013) Kinases conquer the inflammasomes. Nat Immunol 14(12):1207–1208. https://doi.org/10.1038/ni.2763
Newman JC, Verdin E (2014) beta-hydroxybutyrate: much more than a metabolite. Diabetes Res Clin Pr 106(2):173–181. https://doi.org/10.1016/j.diabres.2014.08.009
Okada M, Matsuzawa A, Yoshimura A, Ichijo H (2014) The lysosome rupture-activated TAK1-JNK pathway regulates NLRP3 inflammasome activation. J Biol Chem 289(47). https://doi.org/10.1074/jbc.M114.579961
Pan L, Hang N, Zhang C, Chen Y, Li S, Sun Y, Li Z, Meng X (2017) Synthesis and biological evaluation of novel benzimidazole derivatives and analogs targeting the NLRP3 inflammasome. Molecules 22(2):213–228. https://doi.org/10.3390/molecules22020213
Paris D, Ait-Ghezala G, Bachmeier C, Laco G, Beaulieu-Abdelahad D, Lin Y, Jin C, Crawford F, Mullan M (2014) The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-beta production and Tau hyperphosphorylation. J Biol Chem 289(49):33927–33944. https://doi.org/10.1074/jbc.M114.608091
Periyanayagam S, Arumugam G, Ravikumar A, Ganesan VS (2015) Thymoquinone ameliorates NLRP3-mediated inflammation in the pancreas of albino Wistar rats fed ethanol and high-fat diet. J Basic Clin Physiol Pharmacol 26(6):623–632. https://doi.org/10.1515/jbcpp-2014-0109
Perregaux DG, McNiff P, Laliberte R, Hawryluk N, Peurano H, Stam E, Eggler J, Griffiths R, Dombroski MA, Gabel CA (2001) Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors. J Pharmacol Exp Ther 299(1):187–197
Pinar A, Dowling JK, Bitto NJ, Robertson AA, Latz E, Stewart CR, Drummond GR, Cooper MA, McAuley JL, Tate MD, Mansell A (2017) PB1-F2 peptide derived from avian influenza a virus H7N9 induces inflammation via activation of the NLRP3 inflammasome. J Biol Chem 292(3):826–836. https://doi.org/10.1074/jbc.M116.756379
Pinkerton JW, Kim RY, Robertson AAB, Hirota JA, Wood LG, Knight DA, Cooper MA, O’Neill LAJ, Horvat JC, Hansbro PM (2017) Inflammasomes in the lung. Mol Immunol 86:44–55. https://doi.org/10.1016/j.molimm.2017.01.014
Primiano MJ, Lefker BA, Bowman MR, Bree AG, Hubeau C, Bonin PD, Mangan M, Dower K, Monks BG, Cushing L, Wang S, Guzova J, Jiao A, Lin LL, Latz E, Hepworth D, Hall JP (2016) Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456,773 (CRID3) in murine models of dermal and pulmonary inflammation. J Immunol 197(6):2421–2433. https://doi.org/10.4049/jimmunol.1600035
Qiu J, Wang M, Zhang J, Cai Q, Lu D, Li Y, Dong Y, Zhao T, Chen H (2016) The neuroprotection of Sinomenine against ischemic stroke in mice by suppressing NLRP3 inflammasome via AMPK signaling. Int Immunopharmacol 40:492–500. https://doi.org/10.1016/j.intimp.2016.09.024
Rabkin SW (2009) The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease. Nat Clin Pract Cardiovasc Med 6(3):192–199. https://doi.org/10.1038/ncpcardio1453
Rada B, Park JJ, Sil P, Geiszt M, Leto TL (2014) NLRP3 inflammasome activation and interleukin-1 beta release in macrophages require calcium but are independent of calcium-activated NADPH oxidases. Inflamm Res 63(10):821–830. https://doi.org/10.1007/s00011-014-0756-y
Ron Leuty SFBT (2013) Rigel to cut 30 jobs, focus on three drug programs. https://www.bizjournals.com/sanfrancisco/blog/biotech/2013/09/rigel-fostamatinib-itp-rigl-layoffs.html. Accessed 14 Nov 2017
Salla M, Butler MS, Pelingon R, Kaeslin G, Croker DE, Reid JC, Baek JM, Bernhardt PV, Gillam EM, Cooper MA, Robertson AA (2016) Identification, synthesis, and biological evaluation of the major human metabolite of NLRP3 inflammasome inhibitor MCC950. ACS Med Chem Lett 7(12):1034–1038. https://doi.org/10.1021/acsmedchemlett.6b00198
Schaale K, Peters KM, Murthy AM, Fritzsche AK, Phan MD, Totsika M, Robertson AA, Nichols KB, Cooper MA, Stacey KJ, Ulett GC, Schroder K, Schembri MA, Sweet MJ (2016) Strain- and host species-specific inflammasome activation, IL-1beta release, and cell death in macrophages infected with uropathogenic Escherichia coli. Mucosal Immunol 9(1):124–136. https://doi.org/10.1038/mi.2015.44
Schmid-Burgk JL, Chauhan D, Schmidt T, Ebert TS, Reinhardt J, Endl E, Hornung V (2016) A genome-wide CRISPR (clustered regularly interspaced short palindromic repeats) screen identifies NEK7 as an essential component of NLRP3 inflammasome activation. J Biol Chem 291(1):103–109. https://doi.org/10.1074/jbc.C115.700492
Schroder K, Tschopp J (2010) The inflammasomes. Cell 140(6):821–832. https://doi.org/10.1016/j.cell.2010.01.040
Shanmugam R, Kusumanchi P, Appaiah H, Cheng L, Crooks P, Neelakantan S, Peat T, Klaunig J, Matthews W, Nakshatri H, Sweeney CJ (2011) A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-kappaB and generating reactive oxygen species. Int J Cancer 128(10):2481–2494. https://doi.org/10.1002/ijc.25587
Sheridan C (2017) Novartis trial validates inflammasome as chronic disease driver. Nat Biotechnol 35(10)
Sheth KN, Simard JM, Elm J, Kronenberg G, Kunte H, Kimberly WT (2016) Human data supporting glyburide in ischemic stroke. Acta Neurochir Suppl 121:13–18. https://doi.org/10.1007/978-3-319-18497-5_3
Shi JQ, Zhang CC, Sun XL, Cheng XX, Wang JB, Zhang YD, Xu J, Zou HQ (2013) Antimalarial drug artemisinin extenuates amyloidogenesis and neuroinflammation in APPswe/PS1dE9 transgenic mice via inhibition of nuclear factor-kappaB and NLRP3 inflammasome activation. CNS Neurosci Ther 19(4):262–268. https://doi.org/10.1111/cns.12066
Shi JJ, Zhao Y, Wang YP, Gao WQ, Ding JJ, Li P, Hu LY, Shao F (2014) Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 514(7521):187–192. https://doi.org/10.1038/nature13683
Shi H, Wang Y, Li X, Zhan X, Tang M, Fina M, Su L, Pratt D, Bu CH, Hildebrand S, Lyon S, Scott L, Quan J, Sun Q, Russell J, Arnett S, Jurek P, Chen D, Kravchenko VV, Mathison JC, Moresco EM, Monson NL, Ulevitch RJ, Beutler B (2016) NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component. Nat Immunol 17(3):250–258. https://doi.org/10.1038/ni.3333
Shio MT, Eisenbarth SC, Savaria M, Vinet AF, Bellemare MJ, Harder KW, Sutterwala FS, Bohle DS, Descoteaux A, Flavell RA, Olivier M (2009) Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases. PLoS Pathog 5(8):e1000559. https://doi.org/10.1371/journal.ppat.1000559
Siedle B, Garcia-Pineres AJ, Murillo R, Schulte-Monting J, Castro V, Rungeler P, Klaas CA, Da Costa FB, Kisiel W, Merfort I (2004) Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem 47(24):6042–6054. https://doi.org/10.1021/jm049937r
Strickson S, Campbell DG, Emmerich CH, Knebel A, Plater L, Ritorto MS, Shpiro N, Cohen P (2013) The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system. Biochem J 451(3):427–437. https://doi.org/10.1042/BJ20121651
Studies in natural products chemistry: Volume 52 Bioactive natural products (2017). Elsevier.
Sturm C, Wagner AE (2017) Brassica-derived plant bioactives as modulators of chemopreventive and inflammatory signaling pathways. Int J Mol Sci 18(9):1890–1991. https://doi.org/10.3390/ijms18091890
Sui DM, Xie Q, Yi WJ, Gupta S, Yu XY, Li JB, Wang J, Wang JF, Deng XM (2016) Resveratrol protects against sepsis-associated encephalopathy and inhibits the NLRP3/IL-1beta axis in microglia. Mediat Inflamm 2016:1045657. https://doi.org/10.1155/2016/1045657
Sun Y, Zhao Y, Yao J, Zhao L, Wu Z, Wang Y, Pan D, Miao H, Guo Q, Lu N (2015) Wogonoside protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-kappaB and NLRP3 inflammasome activation. Biochem Pharmacol 94(2):142–154. https://doi.org/10.1016/j.bcp.2015.02.002
Sun Y, Liu W, Zhang H, Li H, Liu J, Zhang F, Jiang T, Jiang S (2017) Curcumin prevents osteoarthritis by inhibiting the activation of inflammasome NLRP3. J Interf Cytokine Res 37(10):449–455. https://doi.org/10.1089/jir.2017.0069
Takahashi M (2014) NLRP3 inflammasome as a novel player in myocardial infarction. Int Heart J 55(2):101–105. https://doi.org/10.1536/ihj.13-388
Terada K, Yamada J, Hayashi Y, Wu Z, Uchiyama Y, Peters C, Nakanishi H (2010) Involvement of cathepsin B in the processing and secretion of interleukin-1beta in chromogranin A-stimulated microglia. Glia 58(1):114–124. https://doi.org/10.1002/glia.20906
Toldo S, Marchetti C, Mauro AG, Chojnacki J, Mezzaroma E, Carbone S, Zhang S, Van Tassell B, Salloum FN, Abbate A (2016) Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemia-reperfusion in the mouse. Int J Cardiol 209:215–220. https://doi.org/10.1016/j.ijcard.2016.02.043
Tucey TM, Verma-Gaur J, Nguyen J, Hewitt VL, Lo TL, Shingu-Vazquez M, Robertson AA, Hill JR, Pettolino FA, Beddoe T, Cooper MA, Naderer T, Traven A (2016) The endoplasmic reticulum-mitochondrion tether ERMES orchestrates fungal immune evasion, illuminating inflammasome responses to hyphal signals. mSphere 1(3). https://doi.org/10.1128/mSphere.00074-16
Van Hauwermeiren F, Lamkanfi M (2016) The NEK-sus of the NLRP3 inflammasome. Nat Immunol 17(3):223–224. https://doi.org/10.1038/ni.3391
van Hout GP, Bosch L, Ellenbroek GH, de Haan JJ, van Solinge WW, Cooper MA, Arslan F, de Jager SC, Robertson AA, Pasterkamp G, Hoefer IE (2016) The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction. Eur Heart J 18(9):828–836. https://doi.org/10.1093/eurheartj/ehw247
Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK (2004) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32(12):1377–1382. https://doi.org/10.1124/dmd.104.000885
Wanderer AA (2009) Corticosteroid resistance in pulmonary neutrophilic inflammatory disorders and rationale for adjunct IL-1beta targeted therapy. Am J Respir Cell Mol Biol 41(2):246–247
Wang WW, Wang C, Ding X-Q, Pan Y, Gu T-T, Wang M-X, Liu Y-L, Wang F-M, Wang S-J, Kong L-D (2013) Quercetin and allopurinol reduce liver thioredoxin-interacting protein to alleviate inflammation and lipid accumulation in diabetic rats. Br J Pharmacol 169(6):1352–1371. https://doi.org/10.1111/bph.12226
Wang C, Zeng L, Zhang T, Liu J, Wang W (2016) Casticin inhibitrs lipopolysaccharide-induced acute lung injury in mice. Eur J Pharmacol 789:172–178. https://doi.org/10.1016/j.ejphar.2016.07.035
Wang HM, Zhang T, Huang JK, Xiang JY, Chen JJ, Fu JL, Zhao YW (2017a) Edaravone attenuates the proinflammatory response in amyloid-beta-treated microglia by inhibiting NLRP3 inflammasome-mediated IL-1beta secretion. Cell Physiol Biochem 43(3):1113–1125. https://doi.org/10.1159/000481753
Wang S, Zhao X, Yang S, Chen B, Shi J (2017b) Salidroside alleviates high glucose-induced oxidative stress and extracellular matrix accumulation in rat glomerular mesangial cells by the TXNIP-NLRP3 inflammasome pathway. Chem Biol Interact 278:48–53. https://doi.org/10.1016/j.cbi.2017.10.012
Wang W, Wu QH, Sui Y, Wang Y, Qiu X (2017c) Rutin protects endothelial dysfunction by disturbing Nox4 and ROS-sensitive NLRP3 inflammasome. Biomed Pharmacother 86:32–40. https://doi.org/10.1016/j.biopha.2016.11.134
Wang Y, Xu CF, Liu YJ, Mao YF, Lv Z, Li SY, Zhu XY, Jiang L (2017d) Salidroside attenuates ventilation induced lung injury via SIRT1-dependent inhibition of NLRP3 inflammasome. Cell Physiol Biochem 42(1):34–43. https://doi.org/10.1159/000477112
Watanabe Y, Nagai Y, Honda H, Okamoto N, Yamamoto S, Hamashima T, Ishii Y, Tanaka M, Suganami T, Sasahara M, Miyake K, Takatsu K (2016) Isoliquiritigenin attenuates adipose tissue inflammation in vitro and adipose tissue fibrosis through inhibition of innate immune responses in mice. Sci Rep 6:23097. https://doi.org/10.1038/srep23097
Wei W, Wang L, Zhou K, Xie H, Zhang M, Zhang C (2017) Rhapontin ameliorates colonic epithelial dysfunction in experimental colitis through SIRT1 signaling. Int Immunopharmacol 42:185–194. https://doi.org/10.1016/j.intimp.2016.11.024
Wen H, Ting JP, O’Neill LA (2012) A role for the NLRP3 inflammasome in metabolic diseases – did Warburg miss inflammation? Nat Immunol 13(4):352–357. https://doi.org/10.1038/ni.2228
Wiersinga WJ, van der Poll T (2007) Is the septic response good or bad? Curr Infect Dis Rep 9(5):366–373. https://doi.org/10.1007/s11908-007-0057-5
Wu J, Xu X, Li Y, Kou J, Huang F, Liu B, Liu K (2014) Quercetin, luteolin and epigallocatechin gallate alleviate TXNIP and NLRP3-mediated inflammation and apoptosis with regulation of AMPK in endothelial cells. Eur J Pharmacol 745:59–68. https://doi.org/10.1016/j.ejphar.2014.09.046
Wu J, Maoqiang L, Fan H, Zhenyu B, Qifang H, Xuepeng W, Liulong Z (2016) Rutin attenuates neuroinflammation in spinal cord injury rats. J Surg Res 203(2):331–337. https://doi.org/10.1016/j.jss.2016.02.041
Xiao M, Li L, Li C, Liu L, Yu Y, Ma L (2016) 3,4-Methylenedioxy-beta-nitrostyrene ameliorates experimental burn wound progression by inhibiting the NLRP3 inflammasome activation. Plast Reconstr Surg 137(3):566e–575e. https://doi.org/10.1097/01.prs.0000479972.06934.83
Xin W, Wang Q, Zhang D, Wang C (2017) A new mechanism of inhibition of IL-1beta secretion by celastrol through the NLRP3 inflammasome pathway. Eur J Pharmacol 814:240–247. https://doi.org/10.1016/j.ejphar.2017.08.036
Xu F, Wang F, Wen T, Sang W, He X, Li L, Zeng N (2017) Protective effect of cinnamic acid in endotoxin-poisoned mice. Phytother Res 31(12):1946–1953. https://doi.org/10.1002/ptr.5944
Yamanashi T, Iwata M, Kamiya N, Tsunetomi K, Kajitani N, Wada N, Iitsuka T, Yamauchi T, Miura A, Pu S, Shirayama Y, Watanabe K, Duman RS, Kaneko K (2017) Beta-hydroxybutyrate, an endogenic NLRP3 inflammasome inhibitor, attenuates stress-induced behavioral and inflammatory responses. Sci Rep 7(1):7677. https://doi.org/10.1038/s41598-017-08055-1
Yang ZJ, Ge WZ, Li QY, Lu Y, Gong JM, Kuang BJ, Xi X, Wu H, Zhang Q, Chen Y (2015) Syntheses and biological evaluation of costunolide, parthenolide, and their fluorinated analogues. J Med Chem 58(17):7007–7020. https://doi.org/10.1021/acs.jmedchem.5b00915
Yang Y, Wang H, Li L, Li X, Wang Q, Ding H, Wang X, Ye Z, Wu L, Zhang X, Zhou M, Pan H (2016) Sinomenine provides neuroprotection in model of traumatic brain injury via the Nrf2-ARE pathway. Front Neurosci 10:580. https://doi.org/10.3389/fnins.2016.00580
Yang SJ, Shao GF, Chen JL, Gong J (2017) The NLRP3 inflammasome: an important driver of neuroinflammation in hemorrhagic stroke. Cell Mol Neurobiol 38(3):595–603. https://doi.org/10.1007/s10571-017-0526-9
Yaron JR, Gangaraju S, Rao MY, Kong X, Zhang L, Su F, Tian Y, Glenn HL, Meldrum DR (2015) K+ regulates Ca2+ to drive inflammasome signaling: dynamic visualization of ion flux in live cells. Cell Death Dis 6:e1954. https://doi.org/10.1038/cddis.2015.277
Yim HC, Williams BR (2014) Protein kinase R and the inflammasome. J Interf Cytokine Res 34(6):447–454. https://doi.org/10.1089/jir.2014.0008
Yonglin Z, Zhaojie W, Fengguang G, Jingsheng W, Hanzhong Z, Wenqiang Z (2017) Wogonoside alleviates inflammation induced by traumatic spinal cord injury by suppressing NF-κB and NLRP3 inflammasome activation. Exp Ther Med 14(4):3304–3308. https://doi.org/10.3892/etm.2017.4904
Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, D’Agostino D, Planavsky N, Lupfer C, Kanneganti TD, Kang S, Horvath TL, Fahmy TM, Crawford PA, Biragyn A, Alnemri E, Dixit VD (2015) The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med 21(3):263–269. https://doi.org/10.1038/nm.3804
Yu H, Wu M, Lu G, Cao T, Chen N, Zhang Y, Jiang H, Fan H, Yao R (2017a) Prednisone alleviates demyelination through regulation of the NLRP3 inflammasome in a C57BL/6 mouse model of cuprizone-induced demyelination. Brain Res 1678:75–84. https://doi.org/10.1016/j.brainres.2017.09.034
Yu X, Zhao Q, Zhang X, Zhang H, Liu Y, Wu X, Li M, Li X, Zhang J, Ruan X, Zhang H (2017b) Celastrol ameliorates inflammation through inhibition of NLRP3 inflammasome activation. Oncotarget 8(40):67300–67314. https://doi.org/10.18632/oncotarget.18619
Zeng J, Chen Y, Ding R, Feng L, Fu Z, Yang S, Deng X, Xie Z, Zheng S (2017) Isoliquiritigenin alleviates early brain injury after experimental intracerebral hemorrhage via suppressing ROS- and/or NF-kappaB-mediated NLRP3 inflammasome activation by promoting Nrf2 antioxidant pathway. J Neuroinflammation 14(1):119. https://doi.org/10.1186/s12974-017-0895-5
Zhang X, Wang G, Gurley EC, Zhou H (2014) Flavonoid apigenin inhibits lipopolysaccharide-induced inflammatory response through multiple mechanisms in macrophages. PLoS One 9(9):e107072. https://doi.org/10.1371/journal.pone.0107072
Zhang A, Wang K, Ding L, Bao X, Wang X, Qiu X, Liu J (2017) Bay11-7082 attenuates neuropathic pain via inhibition of nuclear factor-kappa B and nucleotide-binding domain-like receptor protein 3 inflammasome activation in dorsal root ganglions in a rat model of lumbar disc herniation. J Pain Res 10:375–382. https://doi.org/10.2147/JPR.S119820
Zhao J, Zhang H, Huang Y, Wang H, Wang S, Zhao C, Liang Y, Yang N (2013) Bay11-7082 attenuates murine lupus nephritis via inhibiting NLRP3 inflammasome and NF-kappaB activation. Int Immunopharmacol 17(1):116–122. https://doi.org/10.1016/j.intimp.2013.05.027
Zhao Z, Xiao J, Wang J, Dong W, Peng Z, An D (2015) Anti-inflammatory effects of novel sinomenine derivatives. Int Immunopharmacol 29(2):354–360. https://doi.org/10.1016/j.intimp.2015.10.030
Zhu CS, Xiong ZJ, Chen XH, Peng FH, Hu XQ, Chen YM, Wang Q (2012) Artemisinin attenuates lipopolysaccharide-stimulated proinflammatory responses by inhibiting NF-kappa B pathway in microglia cells. PLoS One 7(4):e35125. https://doi.org/10.1371/journal.pone.0035125
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Robertson, A.A.B. (2018). Inhibiting Inflammasomes with Small Molecules. In: Cordero, M., Alcocer-Gómez, E. (eds) Inflammasomes: Clinical and Therapeutic Implications. Experientia Supplementum, vol 108. Springer, Cham. https://doi.org/10.1007/978-3-319-89390-7_15
Download citation
DOI: https://doi.org/10.1007/978-3-319-89390-7_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-89389-1
Online ISBN: 978-3-319-89390-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)